NanoViricides, Inc. (NYSE: NNVC)'s drug NV-387 could be a single way to treat all of the "tripledemic" viruses and more!
The success of penicillin led to an explosion in the development of antibacterials. But what about fighting viruses? One NYSE-traded biotech company, NanoViricides, Inc. (NYSE: NNVC), is on a solid footing to revolutionize the treatment of antiviral infections with game-changing antiviral nanomedicines. These drugs could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children! The company's lead drug candidate NV-387 is aimed to treat RSV, Covid-19, Long Covid, Influenza, Bird Flu H5N1, and other respiratory viral infections.
NV-387 was substantially superior to the three approved drugs, namely Tamiflu, Rapivab , and Xofluza against an Influenza H3N2 lethal lung viral infection study. NNVC believes that NV-387 is expected to possess strong antiviral activity against H5N1 "Bird Flu" as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387. NV-387 was also at least as good as TPOXX in a model animal study for the development of Smallpox/Mpox drugs, in two different ways of acquiring infection. Additionally, it has been found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin!
| Stockguru LLC (dba InvestingChatter) 711 SW 24th Ave Boynton, Beach, FL 33435 This email is being sent from InvestingChatter. If you no longer wish to receive InvestingChatter emails, please click to unsubscribe. |
| DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. |
No comments:
Post a Comment